Inspire Pharmaceuticals


Former Inspire executive Staab named new BioCryst CFO

BioCryst Pharmaceuticals (NASDAQ:BCRX) has hired former Inspire Pharmaceuticals executive Tom Staab to become the drug developer’s new CFO. Staab starts with Durham, North Carolina-based BioCryst on July 1. Current BioCryst CFO Stuart Grant has agreed to extend his employment an additional month until then. Staab has been executive vice president, CFO and treasurer of Inspire […]


Inspire’s pink eye drug AzaSite draws generic challenge

Pink eye drug AzaSite, a major component of Inspire Pharmaceutical‘s (NASDAQ:ISPH) portfolio and one of the key products sought by Merck (NYSE:MRK) in its $430 million acquisition of the North Carolina company, could soon be facing generic competition. Inspire said in a regulatory filing that generics company Sandoz notified the company that it has submitted […]


Merck’s $430M bid for Inspire followed a 2009 offer

Inspire Pharmaceuticals (NASDAQ:ISPH) CEO Adrian Adams joined the North Carolina company in the winter of 2010 with goals of expanding its business beyond eye products and commercializing a breakthrough cystic fibrosis treatment. In January, one month shy of Adams one-year anniversary at Inspire’s helm and days removed from announcing a failed clinical trial on the […]


Merck to buy Inspire Pharmaceuticals for $430M

Merck (NYSE:MRK) is acquiring Raleigh, North Carolina-based Inspire Pharmaceuticals (NASDAQ:ISPH) for $430 million under a definitive agreement announced Tuesday. Under the agreement, a Merck subsidiary will commence a tender offer for all outstanding shares of Inspire at a price of $5 per share cash. That’s 26 percent more than Inspire’s April 4 close of $3.98. […]


Dry eye drug from Inspire gets patent extension in Japan

Two dry eye therapy patents owned by Inspire Pharmaceuticals (NASDAQ:ISPH) have received extensions in Japan, which gives the drug Diquas patent protection until February 2023. Raleigh, North Carolina-based Inspire disclosed in a securities filing that the extension gives one Diquas patent an additional five years of exclusivity; another patent received approximately 4.5 years of exclusivity. […]